A Phase 4 interventional study of (Empagliflozin 10 mg+ Tab Linagliptin 5mg) and Tab Empagliflozin 10 mg + Tab Metformin 500 mg in Diabete Mellitus, sponsored by Bahria University. Completed at 1 site in Pakistan. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-11-25.
Sponsored by Bahria University · Phase 4, Interventional, and Treatment
The goal of this clinical trial is - Comparison of Empagliflozin - Linagliptin with Empagliflozin - Metformin combination therapy in reduction of body weight in T2DM Patients and it included 200 diabetic subjects with total study period of 12 weeks and individual study period of 4 weeks .
The goal of this clinical trial is to evaluate the safety and efficacy of both the drugs combination in evaluating weight loss and glycemic parameters .
SPSS version 25 will be used to generate the descriptive statistics. Frequency and percentage figures will be used to represent the qualitative factors.
The comparison will be done between male of group A with male of group B and female of group A with female of group B.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 200 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Bahria University is the lead sponsor of 35 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Diabetic men and women of age 40-70 yrs.
Exclusion Criteria:
Male and female type 1 diabetic patients with BMI \<25
Empagliflozin 10 mg, along with Tab Linagliptin 5mg.
Drug: (Empagliflozin 10 mg+ Tab Linagliptin 5mg)
Tab Empagliflozin 10 mg once daily, along with combination of Tab Metformin 500 mg
Drug: Tab Empagliflozin 10 mg + Tab Metformin 500 mg
(Empagliflozin 10 mg+ Tab Linagliptin 5mg)was given once Orally daily
Also known as: Diampa LT (10/5 ) MG, Xenglu- Lin (10 / 5 ) MG, Empaa L ( 10 / 5 ) MG
Tab Empagliflozin 10 mg once daily, along with combination of Tab Metformin 500 mg
Also known as: Xenglu - Met XR ( 10 / 500 ) MG
Overall improvement in Fasting Blood Glucose
Fasting Blood glucose ( mg / dl ) was measured using Glucometer
Time frame: 12 weeks
Overall change in Body Mass Index ( kg/m2)
Body Mass Index ( kg/m2) was recorded using weighing balance and measuring tape .
Time frame: 12 weeks
Overall improvement in Random Blood Glucose
Random Blood Glucose was measured in mg/dl using Glucometer
Time frame: 12 weeks
Over all improvement in Glycated Hemoglobin ( HbA1c)
Blood sample was taken to assess HbA1c
Time frame: 12 weeks
Overall change in Waist to Hip Ratio
Measuring tape was used to measure
Time frame: 12 weeks
Overall change in Waist Circumference
Was measured in inches using measuring tape
Time frame: 12 weeks
To observe adverse effects in treatment groups
1. To evaluate any incidence of Hypoglycemic events during study period 2. To evaluate any incidence of Glycosuria during study period
Time frame: 12 weeks
Plan to share: Yes — All collected IPD data will be shared
Supporting information: Study protocol
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bahria University